| 1 |
34954029 | FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. | 2022 Jan |
2 |
| 2 |
33637776 | BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression. | 2021 Feb 26 |
3 |
| 3 |
34880209 | FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair. | 2021 Dec 8 |
6 |
| 4 |
33069237 | The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. | 2020 Oct 17 |
1 |
| 5 |
28482906 | FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. | 2017 May 8 |
1 |